API Code: SCF-API-TGX-0001
Therapeutic Class: Photonic Neuro-Integrative Multi-Omic Modulator
Indications Covered: Glioblastoma (primary), Neurodegeneration, Retinal Disorders
I. PANEL OBJECTIVE (SCF-ENHANCED)
To construct a next-generation SCF biomarker architecture that validates:
- Neural coherence induction (photonic–cortical axis)
- Tumor metabolic collapse (oncologic axis)
- Retinal–cortical signal restoration (visual axis)
- System-wide multi-omic synchronization (SCF convergence)
This panel extends beyond classical oncology endpoints by integrating connectomics, electrophysiology, and photonic signaling biomarkers.
II. SCF BIOMARKER ARCHITECTURE — 4 AXIS SYSTEM
SCF Axis | Biological Domain | Functional Objective | Endpoint Class |
Axis I | Neural Coherence | Gamma synchronization | Functional |
Axis II | Metabolic Collapse | Tumor energy disruption | Efficacy |
Axis III | Oncologic Suppression | Anti-proliferative + anti-angiogenic | Primary |
Axis IV | Photonic–Visual Integration | Retinal–cortical signaling | Restorative |
Aligned with SCF multi-omic pathophysiology and cross-system reconstruction
III. FULL SCF BIOMARKER PANEL
A. CONNECTOMIC & ELECTROPHYSIOLOGICAL BIOMARKERS (CORE INNOVATION LAYER)
1. Neural Coherence Metrics (PRIMARY DIFFERENTIATOR)
Biomarker | Modality | SCF Role | Endpoint Interpretation |
Gamma EEG coherence (30–80 Hz) | EEG | Neural synchronization | ↑ = therapeutic success |
Phase-locking value (PLV) | EEG | Network stability | ↑ = coherence restoration |
Cross-frequency coupling (theta–gamma) | EEG | Integration index | ↑ = higher-order processing |
Neural entropy (Shannon entropy) | EEG | Signal disorder | ↓ = system stabilization |
2. Connectomics (Network-Level Validation)
Biomarker | Modality | SCF Role | Endpoint |
Functional connectivity (fMRI) | Connectomics | Network integrity | ↑ coherence across cortical hubs |
Default Mode Network (DMN) stability | fMRI | Cognitive baseline | Normalization |
Thalamocortical coupling | fMRI/EEG | Sensory integration | ↑ signal relay efficiency |
B. PHOTONIC–VISUAL BIOMARKERS (NOVEL SCF DOMAIN)
1. Retinal–Cortical Signaling
Biomarker | Modality | SCF Role | Endpoint |
ERG (Electroretinography) amplitude | ERG | Retinal activation | ↑ signal strength |
Visual evoked potentials (VEP) | EEG | Cortical visual response | ↑ latency reduction |
OCT (retinal thickness) | Imaging | Structural integrity | Stabilization |
Photoreceptor response kinetics | ERG | Signal fidelity | ↑ precision |
2. Photonic Signal Integration (Experimental Layer)
Biomarker | Method | SCF Role | Endpoint |
Biophoton emission (UPE) | Photon detection | Cellular coherence | ↑ = improved bioenergetic order |
Mitochondrial photon flux | Spectroscopy | Energy signaling | ↑ efficiency |
Redox-photonic coupling index | Multi-omic integration | Metabolic–photonic link | Stabilization |
C. ONCOLOGIC BIOMARKERS (GLIOBLASTOMA CORE)
1. Signaling Pathway Biomarkers
Biomarker | Pathway | Endpoint |
p-AKT / p-mTOR | PI3K–AKT–mTOR | ↓ = pathway inhibition |
EGFR / EGFRvIII | Proliferation | ↓ expression |
NF-κB (p65) | Inflammation | ↓ activity |
MYC | Tumor growth | ↓ transcription |
2. Angiogenesis & Tumor Microenvironment
Biomarker | Function | Endpoint |
VEGF | Angiogenesis | ↓ levels |
HIF-1α | Hypoxia response | ↓ expression |
Tumor perfusion MRI | Blood supply | ↓ perfusion |
3. Cytotoxic & Apoptosis Markers
Biomarker | Function | Endpoint |
Caspase-3 | Apoptosis | ↑ activation |
Annexin V | Early apoptosis | ↑ binding |
ROS levels | Oxidative stress | Controlled ↑ (tumor-specific) |
D. METABOLOMIC BIOMARKERS (PRIMARY EFFICACY SIGNAL)
Biomarker | Function | Endpoint |
ATP levels | Energy state | ↓ (tumor-specific) |
Lactate | Warburg metabolism | ↓ |
NAD+/NADH ratio | Redox balance | ↑ normalization |
Mitochondrial membrane potential | Bioenergetics | ↓ tumor viability |
E. NEUROTROPHIC & NEUROPLASTICITY BIOMARKERS
Biomarker | Function | Endpoint |
BDNF | Neuroplasticity | ↑ |
TrkB activation | Synaptic growth | ↑ |
Synapsin I | Synaptic density | ↑ |
GABA/Glutamate ratio | Neurobalance | Normalization |
F. IMMUNOLOGIC & NEUROIMMUNE BIOMARKERS
Biomarker | Function | Endpoint |
IL-6, TNF-α | Inflammation | ↓ |
CD8+ T-cell infiltration | Anti-tumor immunity | ↑ |
PD-L1 | Immune evasion | ↓ |
Microglial activation markers | CNS immune status | Stabilization |
G. EPIGENOMIC BIOMARKERS (PLASTICITY & RESISTANCE)
Biomarker | Function | Endpoint |
DNA methylation (global) | Tumor adaptability | Stabilization |
Histone acetylation | Gene expression | Normalization |
miR-21, miR-10b | Oncogenic miRNA | ↓ |
H. IMAGING BIOMARKERS (PRIMARY CLINICAL ENDPOINTS)
Modality | Biomarker | Endpoint |
MRI (RANO criteria) | Tumor volume | ↓ (primary endpoint) |
Diffusion MRI | Cell density | Necrosis ↑ |
PET (FDG) | Glucose metabolism | ↓ uptake |
Perfusion MRI | Angiogenesis | ↓ |
IV. SCF INTEGRATED BIOMARKER CLUSTERS
1. Neural Coherence Cluster
- Gamma EEG ↑
- PLV ↑
- Entropy ↓
Interpretation: Successful cortical synchronization
2. Photonic Integration Cluster
- ERG ↑
- VEP ↑
- Biophoton emission ↑
Interpretation: Restored retinal–cortical signaling
3. Tumor Collapse Cluster
- ATP ↓ + Lactate ↓ + p-mTOR ↓
Interpretation: Metabolic + signaling shutdown
4. Anti-Angiogenic Cluster
- VEGF ↓ + Perfusion ↓
Interpretation: Vascular suppression
5. Neuroprotection Cluster
- BDNF ↑ + Synapsin ↑
Interpretation: Preservation of healthy neural tissue
V. ENDPOINT HIERARCHY (FDA-ALIGNED)
Primary Endpoints
- Tumor volume reduction (MRI, RANO)
- Progression-Free Survival (PFS)
- Overall Survival (OS)
Key Secondary Endpoints
- Gamma coherence normalization
- VEGF reduction
- ATP/lactate metabolic collapse
- Retinal–cortical signal restoration
Exploratory Endpoints
- Biophoton emission dynamics
- Connectome restructuring
- Neurocognitive performance
Aligned with FDA clinical endpoint structure
VI. SAMPLING & TEMPORAL DESIGN
Phase | Biomarker Focus |
Baseline | Genomic, imaging, EEG |
Week 1–2 | EEG, metabolomic |
Month 1 | Proteomic, visual |
Month 2–3 | Imaging + connectomics |
Longitudinal | Immune + epigenomic |
VII. SCF VALIDATION SUMMARY
Parameter | Status |
Multi-omic coverage | Complete |
Novel domains | Photonic + connectomic |
Mechanistic alignment | Full SCF 4-axis |
Clinical readiness | IND-compatible |
Endpoint robustness | High |
MASTER REGISTRY INDEX
- SCF-API-TGX-0001 — THOGALINEX™ API Profile
- SCF-BIO-PANEL-PNI-0001 — Photonic Neuro-Integrative Biomarker Panel
- SCF-PATH-EXT-0001 — SCF Pathophysiology Protocol
- SCF-SEF-MD-0001 — Synergistic Evaluation Framework
- SCF-FDA-REG-0001 — FDA Drug Approval Processes
If you proceed, the next critical deliverable is the SCF Adaptive Clinical Trial Design with biomarker-triggered dosing logic, which will directly operationalize this panel into a precision-guided therapeutic system.